Tveit Solheim Eirik, Vestrheim Thomsen Liv Cecilie, Bjørge Line, Anandan Shamundeeswari, Peter Elise, Desestret Virginie, Totland Cecilie, Vedeler Christian A
Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Departments of Neurology and Clinical Medicine, Neuro-SysMed - Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway.
Ann Clin Transl Neurol. 2024 Dec;11(12):3255-3266. doi: 10.1002/acn3.52232. Epub 2024 Oct 29.
Patients with ovarian cancer (OC) may develop anti-Yo-associated paraneoplastic cerebellar degeneration (PCD)-a cerebellar ataxia associated with tumor-induced autoimmunity against CDR2 and CDR2L proteins. Dysregulation of circulating exosomal microRNAs (miRNAs) occur in OC. Here, we investigated whether PCD is associated with changes in the exosomal miRNA profiles of OC patients.
Serum exosomes were isolated from patients with OC (n = 15), patients with OC and anti-Yo-associated PCD (n = 14) and healthy controls (HC, n = 15). Small RNA sequencing was used to identify differentially expressed miRNAs. Receiver operating characteristic curves were used to evaluate biomarker sensitivity and specificity, and miRNA target prediction analysis was employed to elucidate gene targets.
OC patients with PCD exhibited a distinct exosomal miRNA expression profile. We detected 103 differentially expressed exosomal miRNAs in PCD patients compared to OC patients without PCD and 139 differentially expressed exosomal miRNAs compared to controls. Particularly miR-486-5p, miR-4732-5p, miR-98-5p and miR-21-5p exhibited notable sensitivity and specificity for discriminating PCD patients from both OC patients without PCD and healthy controls. miRNA target prediction showed that several of the differentially expressed miRNAs in PCD patients targeted the CDR2 and CDR2L genes.
Our results demonstrate that OC patients with anti-Yo-associated PCD exhibit a distinct exosomal miRNA profile compared to OC patients without PCD. Several of the differentially expressed exosomal miRNAs in PCD patients showed diagnostic potential and may hold relevance for understanding the pathogenesis of PCD.
卵巢癌(OC)患者可能会发生抗Yo相关的副肿瘤性小脑变性(PCD)——一种与针对CDR2和CDR2L蛋白的肿瘤诱导自身免疫相关的小脑共济失调。循环外泌体微小RNA(miRNA)在OC中发生失调。在此,我们研究了PCD是否与OC患者外泌体miRNA谱的变化相关。
从OC患者(n = 15)、患有OC且有抗Yo相关PCD的患者(n = 14)和健康对照(HC,n = 15)中分离血清外泌体。使用小RNA测序来鉴定差异表达的miRNA。采用受试者工作特征曲线评估生物标志物的敏感性和特异性,并进行miRNA靶标预测分析以阐明基因靶标。
患有PCD的OC患者表现出独特的外泌体miRNA表达谱。与没有PCD的OC患者相比,我们在PCD患者中检测到103种差异表达的外泌体miRNA,与对照组相比有139种差异表达的外泌体miRNA。特别是miR-486-5p、miR-4732-5p、miR-98-5p和miR-21-5p在区分PCD患者与没有PCD的OC患者及健康对照方面表现出显著的敏感性和特异性。miRNA靶标预测表明,PCD患者中一些差异表达的miRNA靶向CDR2和CDR2L基因。
我们的结果表明,与没有PCD的OC患者相比,患有抗Yo相关PCD的OC患者表现出独特的外泌体miRNA谱。PCD患者中一些差异表达的外泌体miRNA显示出诊断潜力,可能与理解PCD的发病机制有关。